KDR and gastric cancer: Recent clinical trials have found that single molecular agent targeting VEGFR-2 (ramucirumab or apatinib) as a salvage therapy may improve progression-free survival (PFS) and OS of patients with advanced GC or gastroesophageal junction cancer (GEJC) [12–14].